25-OCT-2025 6:10

MMYEL ACCRUAL REPORT - Open and Recently Closed Studies

SWOG/
Support		 STUDY R
E
G		 O
P
E
N		 ARM ACCR.
GOAL		 TOTAL
REGS.		 REGS.
LAST
12
Month		 REGS.
LAST
6
Month		 REGS.
LAST
3
Month		 REGS.
LAST
30
DAYS		 REGS.
LAST
7
DAYS		 DATE OF
FIRST
REG.		 # of
ACT.
INSTs		 # of
CURR
IRBs
SWOG S1803-MM, Maintenance, Len vs Len/Dara 1 N 0 Screening 1420 1448 90 0 0 0 0 08/13/2019 26 5
            1448 90 0 0 0 0      
 
    2 Y 1 Lenalidomide   674 51 1 0 0 0 08/13/2019    
        2 Lenalidomide + Daratumumab   664 48 2 0 0 0      
            1338 99 3 0 0 0      
 
    3 Y 3 Stop vs Continue Treatment   275 59 12 0 0 0 08/13/2019    
            275 59 12 0 0 0      
 
  S2005-WM, Prev. Untreated, I/R +/- Venetoclax 1 Y 1 I+R 92 9 7 3 1 0 0 01/05/2022 109 29
        2 I+R+Venetoclax   1 0 0 0 0 0      
        3 V+R   11 8 6 4 2 1      
            21 15 9 5 2 1      
 
  S2209-MM, Newly Dx, VRd-R->R v DRd-R->R v DRD-DR->D 1 Y 1 VRD-R 510 35 21 8 5 2 0 10/12/2023 258 84
        2 DRD-R   35 20 10 5 1 0      
        3 DRD-DR   33 18 8 5 1 1      
            103 59 26 15 4 1      
 
  S2213-AL Amyloidosis, Newly Dx, Dara-VCD v ASCT 1 Y 0 Induction 338 28 23 17 13 5 3 07/01/2024 149 45
            28 23 17 13 5 3      
 
    2 Y 1 Dara-VCD   7 6 4 3 2 1 07/01/2024    
        2 Melphalan + ASCT   6 6 4 2 2 1      
            13 12 8 5 4 2      
 
    3 Y 3 Dara   3 3 2 2 1 0 07/01/2024    
            3 3 2 2 1 0      
 
Yes EAA181-Myel, Newly Dx, DRd=>DRd+/-Btz=>DR (EQUATE) 0 E Total Registrations   61 11 7 3 0 0 05/27/2021 232 81
            61 11 7 3 0 0      
 
    1 E Total Registrations   45 8 6 3 1 0 05/27/2021    
            45 8 6 3 1 0      
 
    2 E Total Registrations   31 5 2 0 0 0 05/27/2021    
            31 5 2 0 0 0      
 
No EAA173-MYEL, SMM, Rd +/- Daratumumab 0 E Total Registrations   80 7 5 2 0 0 01/08/2020 255 102
            80 7 5 2 0 0      
 
    1 E Total Registrations   39 4 2 1 0 0 01/08/2020    
            39 4 2 1 0 0      
 

25-OCT-2025 6:10

MMYEL Open Studies with No Registrations

Study Registration/Phase Open Date # of
ACT.
INSTs		 # of
CURR
IRBs
S2005 WM, Prev. Untreated, I/R +/- Venetoclax 2 Crossover 24-Jun-21 109 29